Anti-Ebola virus therapeutic antibody: Research advances

Author: Chun-Xia QIAO ¹
Author Information

1. Department of Molecular Immunology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences
Publication Type:Journal Article
Keywords: Ebola virus; Therapeutic antibody; ZMapp
From: Journal of International Pharmaceutical Research 2015;42(1):62-68
CountryChina
Language:Chinese
Abstract: Ebola virus (EBOV) is a virulent virus, which can cause the occurrence of EBOV hemorrhagic fever with the mortality of 50%-90% in human and non-human primate (NHP) animal. The biohazard level of Ebola is BSL-4, which is higher than that of AIDS and SARS (BSL-3). Since 2014, the EBOV has spread in West Africa and taken away thousands of lives. At present, the prevention or therapeutic drugs in research against EBOV include vaccines, small molecule drugs and antibodies. Antibodies are relatively safe and specific with fewer side effects. There have reports of several functional antibodies, including monoclonal antibodies 16F6, KZ52 and "antibody cocktails" such as MB-003, ZMAb and ZMapp, which have better efficacy than monovalent antibodies; in China, a similar antibody combination, MIL77, has also completed the preclinical studies for emergency use. In this paper, the development of the antiEbola therapeutic antibodies is reviewed.